Choosing Between Single-Agent and Combination Therapy in Advanced Renal Cell Carcinoma

In this segment on advanced renal cell carcinoma, Dr. Geynisman discusses how clinicians decide between single-agent TKIs and combination approaches in later-line treatment settings. Dr. McGregor and Dr. Wulff highlight that this decision is highly dependent on patient-specific and disease-related factors. Key considerations include performance status, prior treatment history, and tolerance of earlier therapies, as well as the pace of disease progression. The panel notes that single-agent TKIs are often favored in patients who require a more tolerable and manageable approach, particularly those with comorbidities or prior toxicity. In contrast, combination strategies may be considered in select patients who remain fit and may benefit from a more aggressive treatment approach. The discussion emphasizes the importance of balancing efficacy with tolerability and reinforces that treatment selection in later lines of advanced renal cell carcinoma must be individualized based on the overall clinical context.